| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider activity in SNSE over the last quarter tilts toward selling: insiders offloaded a net 34,359 shares worth roughly $600K.
Classified under Biotechnology (Health Care sector), SNSE's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| COO | 1.24M | - | - | |
| Pres | 220.0K | - | - | |
| 10% | 130.6K | $2.61M | - | |
| 10% | 130.6K | $2.61M | - | |
| Other | 80.0K | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 2022 | Cambrian Biopharma Inc | 10% Owner | Buy | 1,203 | $3.20 | $3,849.60 | - | -43.5% | -49.4% | |
| Mar 2, 2022 | Peyer James | Director, 10% Owner | Buy | 1,203 | $3.20 | $3,849.60 | - | -43.5% | -49.4% | |
| Mar 1, 2022 | Cambrian Biopharma Inc | 10% Owner | Buy | 2,500 | $3.60 | $9,000.00 | - | -46.2% | -52.7% | |
| Mar 1, 2022 | Peyer James | Director, 10% Owner | Buy | 2,500 | $3.60 | $9,000.00 | - | -46.2% | -52.7% | |
| Feb 25, 2022 | Cambrian Biopharma Inc | 10% Owner | Buy | 2,500 | $3.65 | $9,125.00 | - | -54.8% | -60.9% | |
| Feb 25, 2022 | Peyer James | Director, 10% Owner | Buy | 2,500 | $3.65 | $9,125.00 | - | -54.8% | -60.9% | |
| Feb 24, 2022 | Cambrian Biopharma Inc | 10% Owner | Buy | 17,500 | $3.65 | $63,950.00 | +0.2% | -55.7% | -60.1% | |
| Feb 24, 2022 | Peyer James | Director, 10% Owner | Buy | 17,500 | $3.65 | $63,950.00 | +0.2% | -55.7% | -60.1% | |
| Feb 18, 2022 | Cambrian Biopharma Inc | 10% Owner | Buy | 19,949 | $4.02 | $80,187.33 | +0.2% | -60.8% | -62.5% | |
| Feb 18, 2022 | Peyer James | Director, 10% Owner | Buy | 19,949 | $4.02 | $80,187.33 | +0.2% | -60.8% | -62.5% |